Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Automatic Tenure-Clock Extensions as a Safeguard Against Defunding.

Annals of internal medicine·2026

Same author

Performance of Stereotactic Radiotherapy vs Hippocampal-Avoidance Whole Brain Radiation.

JAMA oncology·2026

Same author

Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.

Clinical colorectal cancer·2026

Same author

Jurisdiction firearm prevalence and increasing suicide in United States adolescents and young adults.

Journal of the National Medical Association·2025

Same author

Dosimetric evaluations using cycle-consistent generative adversarial network synthetic CT for MR-guided adaptive radiation therapy.

Frontiers in oncology·2025

Same author

National Institutes of Health Funding to Support Radiation Oncology Research: A Comparative Trend Analysis Over a Decade, 2011-2021.

Advances in radiation oncology·2025

Same journal

Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same journal

Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights from a Large-Scale Real-World Chinese Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same journal

Germline Mutations as Risk Factors for Lung Cancer: A Systematic Review and Meta-analysis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same journal

A Response to the Letter to the Editor: Population-informed Assessment of Clonality in Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same journal

Is Less Actually More? Precision Is the Key!

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same journal

A Response to the Letter to the Editor: Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 Targets.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Radiotherapy for thymic neoplasms.

Clifton D Fuller¹, Emma H Ramahi, Noel Aherne

¹Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer

|September 23, 2010

Summary

This summary is machine-generated.

Radiotherapy shows potential benefits for treating thymoma and thymic carcinoma, particularly for specific patient groups. Further research is needed to clarify exact indications and protocols for its use in multidisciplinary care.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

Oncology
Radiation Oncology
Thoracic Surgery

Background:

Thymoma and thymic carcinoma are rare thoracic neoplasms.
Multidisciplinary treatment approaches are standard for these conditions.
The precise role of radiotherapy remains under investigation due to limited data.

Purpose of the Study:

To review the current literature on the use of radiotherapy in thymoma and thymic carcinoma treatment.
To evaluate the potential benefits of radiotherapy in managing these rare cancers.
To identify factors influencing radiotherapy's efficacy in a multidisciplinary setting.

Main Methods:

Systematic review of published literature over the past two decades.
Analysis of small series and population-based studies.
Evaluation of treatment outcomes based on disease stage, grade, and surgical resection extent.

Main Results:

Existing studies are often limited by small sample sizes and long time intervals.
Radiotherapy's role in thymoma and thymic carcinoma management is not definitively established.
Literature suggests potential benefits for select patients based on disease characteristics.

Conclusions:

The optimal indications and protocols for radiotherapy in thymoma and thymic carcinoma are still evolving.
Radiotherapy may offer benefits for specific patient subgroups, contingent on disease stage, grade, and surgical completeness.
Further research is warranted to refine radiotherapy's integration into multimodal treatment strategies.